{ "source": "Cooked Index — occupational AI risk register", "page": "https://cookedindex.com/jobs/biochemists-and-biophysicists/", "methodology": "https://cookedindex.com/methodology", "notice": "Verdicts are re-examined as evidence accumulates. Re-fetch before relying on this; the page above always carries the current score.", "scored_at": "2026-08-11", "model": "claude-opus-5", "occupation": { "title": "Biochemists and Biophysicists", "soc_code": "19-1021", "category": "Science", "us_employment": 33830, "median_annual_wage": 127410 }, "verdict": "EXPOSED", "risk_resistance": 44, "contested": false, "near_boundary": false, "dimensions": { "task_resistance": 10, "embodiment": 12, "liability_shield": 3, "trust_premium": 6, "judgment_accountability": 13 }, "reasoning": { "task_resistance": "At 10 the split is real: the dry-lab half — homology searches, docking runs, kinetics curve-fitting in Prism, RNA-seq pipelines, methods sections — is already model-assisted, while the wet half (cloning a construct that won't ligate, chasing a Western that keeps ghosting, tuning an HPLC gradient for a protein that aggregates at pH 7) still needs a person at the hood, which is why it sits mid-band rather than at 5 or at 15.", "embodiment": "12 reflects hands that matter but in a controlled room: BSL-2 hoods, -80 freezers, ultracentrifuges, mass spec sample prep, plate readers and cryostats are physical and dexterity-dependent, but it's all bench-top in a climate-controlled facility with fixed protocols, not the uncontrolled field conditions that push a score past 13.", "liability_shield": "3 is nearly floor because no state licenses a biochemist — no PE stamp, no board certification, no signature on a regulatory filing; a PhD and a PI's approval get you to the bench, and GLP or IRB requirements attach to the institution and the study director, not to your personal credential.", "trust_premium": "6 is the low end of relationship value: your reviewers are anonymous, your papers are judged on data not on you, and reagent vendors are fungible — the only durable relationships are with the program officer funding the grant and long-term collaborators who know your assay works, which is enough to lift you off the anonymous-output floor but not much further.", "judgment_accountability": "13 sits at the top of the discretion band because you decide whether an outlier is biology or a pipetting error, whether an off-target effect kills a candidate compound, and which mechanism the data actually supports — high-consequence calls, but ones that go through PI review, lab meeting, and peer review before anything irreversible happens, unlike a clinician's bedside decision." }, "rationale": "Roughly half the job is screen work AI now does well or better: literature synthesis, sequence and structure analysis, statistical modeling, figure generation, manuscript and grant drafting — and AlphaFold-class models erased much of the structure-prediction workload outright. What holds is the bench: designing and troubleshooting assays, purifying proteins, running cell culture and instrumentation, and deciding which result is real versus artifact. There is no license or signature requirement, so nothing regulatory protects the analytical tier, and lab automation plus AI compresses how many bodies a project needs.", "outlook": "Headcount stays flat to shrinking as computational work consolidates into fewer, AI-augmented analysts, while bench-based method development and instrument expertise remain hard to hire for.", "what_would_raise_it": { "levers": [ { "dimension": "task_resistance", "change": "As AI absorbs literature synthesis, structure prediction and figure/manuscript drafting, the residual role concentrates on assay design, artifact adjudication and troubleshooting one-off wet-lab failures — genuinely two-tiered work where the judgment tier is the bench. Watch for job postings shifting from 'computational biochemist' to 'assay development / protein science' titles.", "plausibility": "already happening", "would_add": 3 }, { "dimension": "embodiment", "change": "If the field's center of gravity shifts further toward hard-to-automate modalities — cryo-EM sample prep, membrane protein purification, primary cell and organoid culture, single-molecule biophysics rigs — where instrument-specific hands-on troubleshooting dominates, embodiment weight rises. Contrast with cloud-lab/Emerald-style automated pipetting, which cuts the other way.", "plausibility": "plausible", "would_add": 3 }, { "dimension": "liability_shield", "change": "For the subset working under FDA GLP/21 CFR Part 11 or GMP, an FDA or EMA requirement that a named qualified scientist personally attest to AI-derived analytical data and model-generated CMC/potency assay results would create a signature point. The FDA's January 2025 draft guidance on AI in regulatory decision-making for drugs, and EMA's AI reflection paper, are the live documents; a credentialed-attestation clause would be the specific thing to watch.", "plausibility": "plausible", "would_add": 4 }, { "dimension": "judgment_accountability", "change": "If journals and funders extend authorship-accountability rules (ICMJE-style, NIH's 2023 ban on AI in peer review) into a requirement that a named scientist vouch for data provenance and AI-assisted analysis in every submission, and institutions enforce it through research-integrity offices after fabricated-image scandals, the role formally owns the call on what is real.", "plausibility": "already happening", "would_add": 3 }, { "dimension": "trust_premium", "change": "Weak route only: CRO and biotech clients paying for a named PhD to sign off on assay validity because a wrong go/no-go call costs a clinical program — but this is priced as expertise, not human-ness, and AI-assisted competitors underprice it.", "plausibility": "unlikely", "would_add": 1 } ], "ceiling_note": "No licensure exists for the title, so liability protection can only arrive through the pharmaceutical regulatory perimeter and reaches only the industry subset — academic and discovery-stage biochemists get nothing from it. Headcount compression from automation is the dominant force regardless of dimension scores: the remaining judgment tier can be real and still require far fewer people." }, "adjudication": { "method": "two independent runs agreed on the verdict", "outcome": "corroborated", "run_totals": [ 44, 44 ], "run_verdicts": [ "EXPOSED", "EXPOSED" ] }, "employment_history": { "points": [ { "y": 2017, "emp": 27380, "wage": 91190 }, { "y": 2018, "emp": 28500, "wage": 93280 }, { "y": 2019, "emp": 31360, "wage": 94490 }, { "y": 2020, "emp": 32010, "wage": 94270 }, { "y": 2021, "emp": 35050, "wage": 102270 }, { "y": 2022, "emp": 32500, "wage": 103810 }, { "y": 2023, "emp": 33180, "wage": 107460 }, { "y": 2024, "emp": 34520, "wage": 103650 }, { "y": 2025, "emp": 33830, "wage": 127410 } ], "from": 2017, "to": 2025, "change_pct": 23.6, "comparable_from": 2019, "spans_soc_revision": true }, "pivots": [ { "slug": "nuclear-engineers", "title": "Nuclear Engineers", "verdict": "EXPOSED", "risk_resistance": 57, "median_wage": 133970, "overlap": 74, "skills_to_close": [ "Troubleshooting", "Operations Monitoring", "Technology Design", "Operations Analysis" ] } ], "license": "https://cookedindex.com/terms" }